Cerebral Infarction Drugs Market Size

Cerebral Infarction Drugs Market size was valued at USD 7.03 Billion in 2023 and is expected to cross USD 19.34 Billion by the end of 2036, registering more than 8.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cerebral infarction drugs is estimated at USD 7.54 Billion. The growth of the market can be attributed to the increasing frequency of cerebrovascular disease, coupled with the surging prevalence of ischemic strokes throughout the world. For instance, the frequency of ischemic strokes increased to over 7.8 million new ischemic strokes by 2019, which denotes ischemic strokes accounted for more than 63% of all incident strokes worldwide. Further, the worldwide growing ratio of the geriatric population, along with an increase in hypertension rate is another significant factor anticipated to fuel the growth of the global cerebral infarction drugs market over the forecast period.

 In addition to these, factors that are believed to fuel the market growth of cerebral infarction drugs include the rise in population throughout the world as the increasing population has been affected by numerous types of disorders and cerebral infarction can affect any person of any age group. According to the World Bank report, in 2021, the total population of the world has expanded to 7.89 billion. Additionally, the growing awareness in people regarding the cerebrovascular disease, along with the surging investment in developing novel drugs is also estimated to spur market growth throughout the forecast period.